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Abstract
Neuroblastoma is a strongly heterogeneous cancer with very diverse clinical courses
that may vary from spontaneous regression to fatal progression; an accurate pa-
tient’s risk estimation at diagnosis is essential to design appropriate tumor treatment
strategies. Neuroblastoma is a paradigm disease where different diagnostic and
prognostic endpoints should be predicted from common molecular and clinical in-
formation, with increasing complexity, as shown in the FDA MAQC-II study. Here
we introduce the novel multiobjective deep learning architecture CDRP (Concate-
nated Diagnostic Relapse Prognostic) composed by 8 layers to obtain a combined
diagnostic and prognostic prediction from high-throughput transcriptomics data.
Two distinct loss functions are optimized for the Event-Free Survival (EFS) and
Overall Survival (OS) prognosis, respectively. We use the High-Risk (HR) diag-
nostic information as an additional input generated by an autoencoder embedding.
The latter is used as network regulariser, based on a clinical algorithm commonly
adopted for stratifying patients from cancer stage, age at insurgence of disease, and
MYCN, the specific molecular marker. The architecture was applied to Illumina
HiSeq2000 RNA sequencing of 498 neuroblastoma patients (176 at high risk)
from the Sequencing Quality Control (SEQC) study, obtaining state-of-art on the
diagnostic endpoint and improving prediction of prognosis over the HR cohort.
Introduction The challenge of dealing with multiple endpoints of clinical interest is a hallmark of
predictive models from high-throughput molecular data, as demonstrated in the MAQC-II (Microarray
Analysis and Quality Control) Study [1]. Neuroblastoma is a paradigmatic example of disease where
the medical community has adopted a clinical algorithm that defines the subtype of cancer patients
with lowest expectation of response to therapy and survival, but the precision medicine approach is
still failing to identify molecular profiles clearly associated to patient subtypes. Especially for High
risk (HR) patients, adequate therapies are still lacking.
Arising predominantly in the first two years of life, neuroblastoma is the most frequent extracranial
solid tumor in infancy, accounting for about 500 new cases in Europe per year (130 in Germany),
corresponding to roughly 8% of pediatric cancers and 15% of pediatric oncology deaths [2]. Neu-
roblastoma develops from the immature cells of the ganglionic sympathetic nervous system lineage
stemming from the neural crest cells, and tumors can arise at any site where sympathetic neuroblasts
are present during normal development [3], e.g., in chest. The broad variety of clinical behavior
represent neuroblastoma’s major hallmark, ranging from spontaneous regression (stage 4S) to gradual
maturation (stages 1-2) to aggressive and often fatal ganglioneuroma [4, 5] (stages 3-4), despite inten-
sive multimodal treatment. Official staging is defined by the International Neuroblastoma Staging
System (INSS) [6]. The current strategies used to appropriately design tumor treatment therapies
use different combinations of clinical and genetic markers to discriminate patients with low or high
risk of death from disease. The markers used in this diagnosis include age [7], tumor stage [8, 9]
and MYCN proto-oncogene genomic amplification [10, 11]. However, this standard protocol is still
imperfect, often resulting in over- or undertreatment of patients with neuroblastoma [12]. Cancer
genetic instability is most often studied at the genomic and gene expression levels, focusing on the
effects of genomic alterations on transcription and splicing. In fact, several studies demonstrated that
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using messenger RNA (mRNA) expression information for molecular classification improves the
diagnostic accuracy over traditional clinical markers for individual tumor behavior, enhancing the
risk stratification reliability and therefore the therapy selection [13, 14, 15, 16, 17, 18, 1, 19]. Only a
limited number of the published classifiers based on gene expression have been so far incorporated
into clinical operative systems for a controlled validation trial: as examples, [20, 21] and the U.S.
National Institutes of Health clinical trials [22, 23]. The reasons are diverse and include logistic and
bureaucratic hindrances for the implementation of classifiers into clinical practice, difficulties in the
setup of controlled validation trials for relatively small patient numbers, and the challenge to appro-
priately design the therapy according to genomic classification results. Moreover, prognostic gene
expression signatures for neuroblastoma stemming from different methodologies applied to different
datasets often identify diverse gene sets [24, 25]. Thus, the impact of genomic classification-induced
treatment on the outcome of neuroblastoma patients is still an open issue. As a contribute, we present
here a novel multi-objective deep learning [26] solution named CDRP (Concatenated Diagnostic
Relapse Prognostic) that accurately classifies patients in a internationally collected neuroblastoma
cohort, by combining both prognostic and diagnostic information from gene expression data. An
artificial neural network (multilayer perceptron) has been used for neuroblastoma outcome predic-
tion [27] from expression data but in a shallow learning framework. Deep learning based approaches
have also appeared in the neuroblastoma literature, but using images rather than omics inputs [28].
Our architecture is built in multiple steps. We train on half of the patients a multitask net CDRP-N
for classification over two distinct prognostic tasks at 5-years, namely Event-Free Survival (EFS:
events are relapse, disease progression or death), and the Overall Survival (OS: partitioning patients
as either dead or alive). Furthermore, the shared layer of the multitask net has additional inputs from
another network modeling the high-risk (HR: high risk, non high-risk or unknown status) endpoint.
In detail, we link values from the embedding of an autoencoder CDRP-A developed over the same
training data for the HR diagnostic task. In order to control for selection bias, both the net CDRP-N
and the autoencoder CDRP-A are trained and evaluated using a Data Analysis Protocol (DAP),
based on a 10×5-fold cross validation developed within the MAQC-II and SEQC studies led by the
US-FDA [1, 29]. We apply the CDRP-N–CDRP-A architecture on the RNA sequencing (RNA-Seq)
dataset from the SEQC study [29, 30]. The same dataset split employed in the Neuroblastoma SEQC
satellite study is adopted for comparability [30]. We obtain consistent or improved performance with
CDRP-N with respect to SVM or Random Forest models. Operatively, the framework is implemented
in a Keras [31] environment over a Tensorflow [32] backend, run on a nVidia Pascal-GPU Blade
equipped with two GTX 1080, 8 GB dedicated RAM, 2560 CUDA cores, up to 9TFlops throughput
and 8 CPU Intel Core i7–6700 with 32 GB RAM.
Data description The dataset used in this study collects RNA-Seq gene expression profiles of
498 neuroblastoma patients, published as part of the SEQC initiative [29, 30]. We considered the
following endpoints for classification tasks: the occurrence of an event (progression, relapse or
death) (Event-Free survival, “EFS”); the occurrence of death from disease (Overall Survival, “OS”);
the occurrence of an event (“EFSHR”) and death from disease (“OSHR”) in high-risk (HR) patients
only. HR status was defined according to the NB2004 risk stratification criteria. The samples
were split into training (NBt) and validation (NBv) sets following a published partitioning [30].
Stratification statistics for NBt and NBv are reported in Tab. 1. RNA-Seq data were preprocessed
as log2 normalized expressions for 60,778 genes (“MAV-G”) [30]. Expression tables were filtered
before downstream analyses by removing features without EntrezID and with interquartile range
(IQR) > 0.5 using the nsFilter function in the genefilter R package, leaving 12,464 (20.5%) genes
for downstream analysis. To avoid information leakage, feature filtering was performed on NBt data
set and applied on both NBt and NBv sets.
The deep learning architecture The architecture of two deep learning solutions CDRP-N and
CDRP-A are shown in Fig. 1. For both, the neural network is developed within a DAP described
in detail in the next section. The autoencoder CDRP-A is used as a regressor on the HR/non-HR
task, aimed at minimizing the mean square error mse. The input layer is selected by the DAP K-best
algorithm to be of dimension 250 (2% of the total number of features), corresponding to the best value
mse = 0.042 with confidence interval (0.041; 0.043). This is followed by two dense layers with
128 nodes with tanh activation, ending in another dense layer with 64 nodes with linear activation.
The output is later used as the HR embedding input for the shared merge layer in CDRP-N . A
specular decoding structure (dotted boxes and arrows in Fig. 1) exists but is not used by CDRP-N .
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Table 1: Sample stratification (left) and summary statistics (right) for the NBt and NBv subset for the
covariates High-Risk (HR), Overall Survival (OS) and Event-Free Survival (EFS). HR 0:non high
risk/NA (green), 1:high risk (red), EFS 0:no event (green), 1:event (red), OS 0:alive (green), 1:dead
(red).
HR EFS OS NBt NBv
0
0 0 129 130
1 0 26 241 8 5
1
0 0 31 25
1 0 12 161 43 49
0 1
HR NBt 163 86NBv 159 90
EFS NBt 160 89NBv 155 94
OS NBt 198 51NBv 195 54
The classification net CDRP-N starts with an initial layer taking as input the whole set of 12,646
features. This is followed by two dense layers, with 256 and 128 nodes, respectively. The output of
this last layer is merged with concatenation with the HR embedding layer computed by CDRP-A,
obtaining a shared layer from which two different branches depart. Up to this layer, all activations are
LeakyReLU function [33, 34] with coefficient 0.3, with no dropout [35] nor batch normalization [36].
The first branch consists of a single output layer with 8 nodes and softmax activation on the EFS
task, while the second branch has two layers, first a 32-node dense one and then a 16-ndoe dense
softmax activated output layer for the OS task. The loss function for the OS task has weight 2, while
for EFS the weight is 1. Across all CDRP-N the batch size is 64, and the optimizer is Adadelta [37]
with δ = 0 and η = 1. Finally, for CDRP-N the number of epochs is bounded to 500, with an
early stopping rule on the validation loss, with patience 4 and min∆ 10−6, while CDRP-A has 2000
epochs without early stopping.
The analysis pipeline The experimental methodology outlined in Fig. 2 follows the DAP developed
in the context of the MAQC-II challenge [1], the U.S. Food and Drug Administration (FDA) initiative
aimed to establish reproducibility in microarray gene expression experiments. Given a dataset divided
in a training and a test set, the former undergoes a 10× 5−fold Stratified Cross Validation resulting
in ranked list of features and a classification performance measure, here the Matthews Correlation
Coefficient [38, 39] MCC = TP·TN−FP·FN√
(TP+FP)(TP+FN)(TN+FP)(TN+FN)
, for TN, TP, FN, FP the entries of
the binary confusion matrix. Data are mean zero and variance one and log2 transformed before
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Figure 1: The layer/node structure of the proposed deep learning architecture CDRP.
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Figure 2: The Data Analysis Protocol (DAP) used in the experiments, originally defined in the
US-FDA MAQC-II initiative.
Table 2: Comparison of the median MCC from the SEQC study in cross-validation (“NBt”) and
external validation (“NBv”) with the MCC obtained by CDRP-N . For LSVM, RF,Ns and CDRP-N ,
95% studentized bootstrap confidence intervals for NBt are also reported. The chosen architecture
CDRP-N was the best performing in cross-validation on NBt. MCC values for CDRP-N on EFSHR
and OSHR are inherited from the values on the overall cohort, with no retraining.
Task SEQC LSVM RF Ns CDRP-N
NBt NBv NBt NBv NBt NBv NBt NBv NBt NBv
EFS 0.45 0.50 0.46 (0.43;0.49) 0.48 0.45 (0.41;0.48) 0.52 0.40 (0.36;0.45) 0.41 0.42 (0.38;0.45) 0.45
OS 0.48 0.47 0.46 (0.42;0.50) 0.47 0.43 (0.39;0.47) 0.37 0.48 (0.46;0.53) 0.48 0.50 (0.45;0.54) 0.57
EFSHR 0.34 0.16 0.13 (0.08;0.18) 0.21 0.17 (0.10;0.23) 0.13 0.15 (0.09;0.22) 0.19 0.18 (0.11;0.25) 0.38
OSHR 0.36 0.07 0.22 (0.16;0.28) 0.12 0.33 (0.26;0.39) 0.10 0.23 (0.21;0.35) 0.14 0.25 (0.19;0.31) 0.19
undergoing classification, and in order to avoid information leakage standardization parameters from
the training set are used for both training and test subsets. The k-best algorithm is chosen as the
feature ranker, and the classification is performed using the deep learning architecture previously
described, and the best model is later retrained on the whole training set and selected for validation
on the test set. Furthermore, as a sanity check to avoid unwanted selection bias effects, the pipeline is
repeated 20 times with two randomized strategies: a Random Label scheme where the true training
labels are stochastically scrambled, and a Random Feature scheme where a random set of features is
selected instead of the optimal list.
Results and discussion CDRP is a novel multitask deep learning architecture that improves pre-
diction of hard prognostic endpoints by injecting latent variables from autoencoding the standard
clinical model. The performance of the CDRP architecture is summarized in Tab. 2. CDRP improves
MCC in validation for the OS endpoint, and it is the first model to improve on the High Risk cohort
(EFS-HR, OS-HR). A theoretical basis justifying the achieved improvement relies on the fact that
the information distilled from the diagnostic task adds clinical information, used by the multi-task
predictor, which combines the OS and EFS tasks. Finally, CDRP models with random labels yield
MCC ≈ 0, indicating honest estimates, while consistent results are obtained also with swapped
training and validation sets. Retraining of CDRP-N on the HR subset is especially computing
intensive and will be added in a future version of the paper. Further refinement will include the
extraction of enriched pathways for genes derived from the activation in the shared layer.
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